Research programme: deuterium-containing drug - Teva Pharmaceutical Industries
Latest Information Update: 20 Jun 2013
At a glance
- Originator Auspex Pharmaceuticals
- Developer Auspex Pharmaceuticals; Teva Pharmaceutical Industries
- Class Organic deuterium compounds
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 20 Jun 2013 No development reported - Preclinical for Undefined indication in USA (unspecified route)
- 21 Dec 2010 Preclinical trials in Undefined indication in USA (unspecified route)